NASDAQ:NXL Nexalin Technology (NXL) Stock Price, News & Analysis → FW: 234x Gain (From Weiss Ratings) (Ad) Free NXL Stock Alerts $1.44 -0.21 (-12.77%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$1.43▼$1.6450-Day Range$0.31▼$2.8752-Week Range$0.25▼$3.40Volume51,718 shsAverage Volume254,934 shsMarket Capitalization$10.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Nexalin Technology alerts: Email Address Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Nexalin Technology Stock (NASDAQ:NXL)Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. In addition, it designs and develops Generation 2 and Generation 3, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, Alzheimer's disease, and dementia. The company is based in Houston, Texas.Read More NXL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NXL Stock News HeadlinesApril 26, 2024 | americanbankingnews.comNexalin Technology, Inc. (NASDAQ:NXL) Short Interest Up 243.7% in AprilApril 25, 2024 | finanznachrichten.deNexalin Technology, Inc.: Nexalin Technology Regains Compliance with Nasdaq Continued Listing RequirementsMay 4, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 25, 2024 | globenewswire.comNexalin Technology Regains Compliance with Nasdaq Continued Listing RequirementsApril 12, 2024 | investing.comNexalin Technology advances in mental health treatmentApril 10, 2024 | globenewswire.comNexalin Technology CEO Provides Letter to ShareholdersApril 6, 2024 | stockhouse.comNexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity(TM), a Non-Invasive, Frequency-Based Deep-Brain Stimulation DeviceApril 4, 2024 | globenewswire.comNexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation DeviceMay 4, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 2, 2024 | proactiveinvestors.comNexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veteransApril 2, 2024 | globenewswire.comNexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory BoardMarch 30, 2024 | finance.yahoo.comNexalin Technology Full Year 2023 Earnings: US$0.63 loss per share (vs US$0.30 loss in FY 2022)March 28, 2024 | globenewswire.comNexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San DiegoMarch 14, 2024 | finance.yahoo.comNexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s TechnologyMarch 14, 2024 | globenewswire.comNexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's TechnologyMarch 13, 2024 | globenewswire.comNexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”March 6, 2024 | globenewswire.comNexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic InsomniaFebruary 8, 2024 | finance.yahoo.comNexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation DeviceJanuary 23, 2024 | finance.yahoo.comNexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) SystemJanuary 17, 2024 | morningstar.comNexalin Technology Inc NXLJanuary 11, 2024 | stockhouse.comNexalin Technology Unveils Next-Generation HALO(TM) ClarityJanuary 11, 2024 | finance.yahoo.comNexalin Technology Unveils Next-Generation HALO™ ClarityDecember 18, 2023 | finance.yahoo.comNexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant DepressionOctober 16, 2023 | finance.yahoo.comNexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain StructuresSeptember 14, 2023 | barrons.comNexalin Technology Inc.August 7, 2023 | finance.yahoo.comNexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related SymptomsAugust 3, 2023 | finance.yahoo.comNexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern TimeSee More Headlines Receive NXL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nexalin Technology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/04/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:NXL CUSIPN/A CIK1527352 Webwww.nexalin.com Phone832-260-0222FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,650,000.00 Net Margins-4,185.46% Pretax Margin-4,197.82% Return on Equity-122.57% Return on Assets-97.00% Debt Debt-to-Equity RatioN/A Current Ratio8.07 Quick Ratio7.70 Sales & Book Value Annual Sales$110,000.00 Price / Sales97.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.43 per share Price / Book3.34Miscellaneous Outstanding Shares7,440,000Free Float5,378,000Market Cap$10.68 million OptionableNot Optionable Beta5.80 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMs. Marilyn Elson (Age 71)Controller Comp: $382.72kMr. Mark White (Age 62)President, CEO, CFO & Director Comp: $191.29kMr. John Patrick ClaudeCo-Founder and Director of Engineering & DevelopmentDr. David Owens M.D. (Age 63)Chief Medical Officer & Director Mr. Michael Nketiah (Age 48)Senior Vice-President of Quality, Regulatory & Clinical Affairs Comp: $251.6kKey CompetitorsSymbolic LogicNASDAQ:EVOLMaris-TechNASDAQ:MTEKSimppleNASDAQ:SPPLIdeanomicsNASDAQ:IDEXLendwayNASDAQ:LDWYView All Competitors NXL Stock Analysis - Frequently Asked Questions How have NXL shares performed in 2024? Nexalin Technology's stock was trading at $0.4048 on January 1st, 2024. Since then, NXL stock has increased by 254.5% and is now trading at $1.4350. View the best growth stocks for 2024 here. Are investors shorting Nexalin Technology? Nexalin Technology saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 327,200 shares, an increase of 243.7% from the March 31st total of 95,200 shares. Based on an average daily trading volume, of 786,600 shares, the short-interest ratio is currently 0.4 days. Approximately 5.6% of the shares of the company are short sold. View Nexalin Technology's Short Interest. When is Nexalin Technology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our NXL earnings forecast. When did Nexalin Technology IPO? Nexalin Technology (NXL) raised $10 million in an initial public offering on Friday, September 16th 2022. The company issued 2,315,000 shares at a price of $4.15 per share. How do I buy shares of Nexalin Technology? Shares of NXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NXL) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchStock-Picking AI Predicts #1 Stock of 2024AltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nexalin Technology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
